​An Investigator in the Section on Immunobiology, Dr. Serwold studies how T cells of the immune-system cells are generated—research that helps to shed light on what causes type 1 diabetes and other autoimmune diseases.

Type 1 diabetes results from an autoimmune attack on the insulin-producing beta cells of the pancreas.  This autoimmune attack is driven primarily by T cells that mistakenly react to beta cell products.  The Serwold lab studies these T cells, in order to determine approaches to efficiently inactivate them in order to halt diabetes progression, or to enable beta cell transplantation.

We have recently shown that eliminating certain specific populations of autoimmune T cells can prevent diabetes in animal models.  We have engineered cytotoxic T cells to express novel, biomimetic chimeric antigen receptors that specifically kill certain autoimmune T cells, and have transplanted these engineered T cells into diabetes prone mice, and found that they confer protection to diabetes. We are using this novel approach to identify the key autoimmune T cell populations in type 1 diabetes, the timing of their activity and what stages they can be eliminated to prevent diabetes development. We are also optimizing and determining the therapeutic potential of this approach.

Contact Information

Office Phone

(617) 309-2530

thomas.serwold [at] joslin.harvard.edu

News Related to Thomas Serwold